Original Article
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
N Engl J Med 2008; 359:1429-1441October 2, 2008
- Abstract
Background
CC chemokine receptor 5 antagonists are a new class of antiretroviral agents.
Methods
We conducted two double-blind, placebo-controlled, phase 3 studies — Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 — with patients who had R5 human immunodeficiency virus type 1 (HIV-1) only. They had been treated with or had resistance to three antiretroviral-drug classes and had HIV-1 RNA levels of more than 5000 copies per milliliter. The patients were randomly assigned to one of three antiretroviral regimens consisting of maraviroc once daily, maraviroc twice daily, or placebo, each of which included optimized background therapy (OBT) based on treatment history and drug-resistance testing. Safety and efficacy were assessed after 48 weeks.
Results
A total of 1049 patients received the randomly assigned study drug; the mean baseline HIV-1 RNA level was 72,400 copies per milliliter, and the median CD4 cell count was 169 per cubic millimeter. At 48 weeks, in both studies, the mean change in HIV-1 RNA from baseline was greater with maraviroc than with placebo: –1.66 and –1.82 log10 copies per milliliter with the once-daily and twice-daily regimens, respectively, versus –0.80 with placebo in MOTIVATE 1, and –1.72 and –1.87 log10 copies per milliliter, respectively, versus –0.76 with placebo in MOTIVATE 2. More patients receiving maraviroc once or twice daily had HIV-1 RNA levels of less than 50 copies per milliliter (42% and 47%, respectively, vs. 16% in the placebo group in MOTIVATE 1; 45% in both maraviroc groups vs. 18% in MOTIVATE 2; P<0.001 for both comparisons in each study). The change from baseline in CD4 counts was also greater with maraviroc once or twice daily than with placebo (increases of 113 and 122 per cubic millimeter, respectively, vs. 54 in MOTIVATE 1; increases of 122 and 128 per cubic millimeter, respectively, vs. 69 in MOTIVATE 2; P<0.001 for both comparisons in each study). Frequencies of adverse events were similar among the groups.
Conclusions
Maraviroc, as compared with placebo, resulted in significantly greater suppression of HIV-1 and greater increases in CD4 cell counts at 48 weeks in previously treated patients with R5 HIV-1 who were receiving OBT. (ClinicalTrials.gov numbers, NCT00098306 and NCT00098722.)
Media in This Article
Figure 1
Screening, Randomization, and Completion of Treatment.Figure 2
Treatment Responses at 48 Weeks.Article Activity
- Article
For the past decade, treatment of human immunodeficiency virus type 1 (HIV-1) has consisted of a multiple-drug regimen targeting one or more of three HIV-1 proteins: reverse transcriptase, protease, and the glycoprotein envelope subunit gp41.1 Although these antiretroviral combinations are successful in suppressing viral replication and delaying disease progression, drug resistance and toxic effects may occur.2-4 There is therefore a need for better-tolerated, convenient antiretroviral agents with reduced toxicity and activity against multidrug-resistant viruses.
Agents with novel mechanisms of action provide options for patients with drug-resistant virus.4 CC chemokine receptor 5 (CCR5) is an attractive therapeutic target, since people with the delta32 deletion in both copies of the CCR5 gene lack CCR5 on the cell surface and are relatively resistant to HIV infection, whereas people who are heterozygous for the deletion have reduced expression of CCR5 on the cell surface and have delayed declines in the CD4 cell count and slower progression of HIV disease.5-8 These data support the rationale for testing CCR5 antagonists in people infected with R5 HIV-1. R5 HIV-1 predominates in the early stages of infection, whereas the X4 virus may emerge over time.9,10 The results of coreceptor-tropism assays in patients for whom at least two antiretroviral regimens have failed indicated that 50 to 62% were infected with R5 HIV-1 only.11-13 Thus, a sizable proportion of previously treated patients may benefit from treatment with a CCR5 antagonist. Maraviroc binds specifically and selectively to CCR5 on the surface of the CD4 cell and blocks HIV-1 binding.14-16 Maraviroc has potent activity against R5 HIV-1 strains in vitro, including drug-resistant isolates.14 In asymptomatic patients with HIV-1 infected with R5 virus only, as shown by a coreceptor-tropism assay, 10 days of maraviroc monotherapy reduced levels of HIV-1 RNA by nearly 2 log10 copies per milliliter.17 In contrast, maraviroc conferred little or no virologic benefit in patients with evidence of X4 HIV-1 strains.18
The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) studies 1 and 2 were designed to evaluate the efficacy and safety of maraviroc once daily or twice daily, as compared with placebo, when added to optimized background therapy (based on treatment history and drug-resistance testing) in patients with R5 HIV-1 who had previously been treated with three classes of antiretroviral drugs or who had resistant virus.
Methods
Study Design
MOTIVATE 1 and MOTIVATE 2 are parallel, randomized, double-blind, placebo-controlled, multinational phase 3 studies. The trials were designed with a 48-week treatment period, preceded by a 4-to-6-week screening period, and incorporated a single planned interim analysis at 24 weeks and an extension to 96 weeks. MOTIVATE 1 was conducted in Canada and the United States, and MOTIVATE 2 in Australia, Europe, and the United States. The design, conduct, and protocol-specified analyses were identical for the two studies.
At the screening visit, previous antiretroviral treatment was assessed, safety laboratory tests were conducted, and all patients underwent testing for HIV-1 coreceptor tropism with the use of a validated phenotypic assay (Trofile, Monogram Biosciences).19,20 Patients were also tested for plasma levels of HIV-1 RNA (Amplicor HIV-1 Monitor v1.5, Roche Diagnostics) and genotypic and phenotypic resistance to approved antiretroviral drugs (PhenoSense GT assay, Monogram Biosciences), including gp41 sequencing for enfuvirtide resistance (British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada).
At the time of randomization, 4 to 7 days before administration of the first dose of the study drug, a second HIV-1 RNA measurement was obtained. An antiretroviral regimen to be used as optimized background therapy was selected by the investigator on the basis of the treatment history, safety considerations, and drug-resistance test results, in consultation with the study's medical monitor. Eligible patients were randomly assigned in a 2:2:1 ratio to receive optimized background therapy in combination with maraviroc once daily, maraviroc twice daily, or matching placebo. Patients were stratified at the time of randomization according to the use or nonuse of enfuvirtide and the plasma HIV-1 RNA level at the time of screening (<100,000 or ≥100,000 copies per milliliter).
Treatment failure was defined as one or more of four virologic end points (confirmed by a second consecutive measurement within 14 days): an increase in the level of HIV-1 RNA to a value that was at least three times the baseline level at or after week 2; a decrease of less than 0.5 log10 copies per milliliter at or after week 8; a decrease of less than 1.0 log10 copies per milliliter at or after week 8, after a decrease of 2.0 or more log10 copies per milliliter; and an increase to 5000 or more copies per milliliter after levels of 400 copies or less per milliliter had been recorded on two consecutive visits. Coreceptor tropism and drug-resistance testing were performed in all patients who met these criteria, as well as in patients who had HIV-1 RNA levels of 500 copies per milliliter or more at or after week 4 (for tropism) or at weeks 24 and 48 (for drug resistance).
The study protocol was approved by the institutional review board or independent ethics committee at each study center. Written informed consent was obtained from all participants. The studies were performed in accordance with International Conference on Harmonization Good Clinical Practice guidelines and applicable local regulatory requirements and laws. An independent data and safety monitoring board was responsible for oversight of the progress of the studies, the study data, and safety considerations.
The study was designed by the sponsor, Pfizer Global Research and Development, with input from the study investigators. Data were gathered by the study investigators and the sponsor, with data summaries provided by an independent statistician (Covance CAPS, Berkshire, United Kingdom) from the Statistical Data Analysis Center to the data and safety monitoring board for periodic review. All statistical analyses were carried out by the study sponsor according to a predefined plan. Two of the authors wrote the paper, with extensive input from the study team. The study team vouches for the accuracy and completeness of the data and analysis as presented.
Study Population
All patients were at least 16 years old, were infected with R5 HIV-1 only (as shown by a coreceptor tropism assay), and had taken one or more agents from three antiretroviral classes (nucleoside analogues, non-nucleoside analogues, protease inhibitors [at least two drugs from this class], or fusion inhibitors) for 6 months or more or had documented genotypic or phenotypic resistance to drugs from at least three of these classes. Patients had been receiving a stable antiretroviral regimen or no antiretroviral therapy for more than 4 weeks and had a plasma HIV-1 RNA level of more than 5000 copies per milliliter at the screening visit. Patients were ineligible if there was evidence of infection with X4 HIV-1, if the tropism assay failed to show a result, or if they had received any investigational HIV-entry inhibitor for more than 14 days.
Study Medication
In addition to optimized background therapy, patients received oral maraviroc or placebo (twice daily), without regard to food; the study drugs were identical in appearance. Maraviroc doses equivalent to 300 mg once or twice daily were selected on the basis of prior drug–drug interaction data, with patients whose optimized background therapy included a protease inhibitor (other than tipranavir) or delavirdine receiving maraviroc at a once- or twice-daily dose of 150 mg.17,21,22 With all other regimens, patients received 300 mg of maraviroc once or twice daily. Optimized background therapy, selected by the investigator on the basis of the treatment history and drug-resistance testing, comprised three to six open-label–approved antiretroviral agents (with or without low-dose ritonavir), chosen from nucleoside analogues, nonnucleoside analogues, protease inhibitors, and fusion inhibitors. Use of tipranavir was permitted after drug–drug interaction data became available (February 2006). Investigational agents (at the time including darunavir, etravirine, and raltegravir) were not permitted. If there were toxic effects that could be attributed to a specific component of optimized background therapy, a drug of the same class could be substituted after consultation with the study's medical monitor.
Efficacy Analysis
The primary end point was the mean change in log10-transformed levels of HIV-1 RNA from baseline to 48 weeks. This end point was consistent with both treatment guidelines1 and published studies of investigational agents in this patient population.23,24 Secondary end points included HIV-1 RNA levels of less than 50 and less than 400 copies per milliliter, a decrease in HIV-1 RNA from baseline of 1.0 log10 copies per milliliter or more, a change in the CD4 cell count from baseline, and time to treatment failure.
Safety Analysis
Safety end points included adverse events, adverse events leading to discontinuation of the study drug, serious adverse events (including death and category C events — i.e., acquired immunodeficiency syndrome [AIDS]–defining events),25 and laboratory-test abnormalities. Study procedures included monitoring patients for adverse events and performing laboratory tests for safety at all study visits, measuring vital signs, and obtaining a 12-lead electrocardiogram at selected study visits. Adverse events were graded in accordance with the adverse-event grading scale developed by the Division of AIDS at the National Institutes of Health,26 with causality assessed by the investigator.
Statistical Analysis
Assuming a standard deviation of 0.8, with a two-sided significance level of 0.025 (with Bonferroni's adjustment for multiple comparisons of the primary end point), we calculated that a sample of 500 patients (randomly assigned in a 2:2:1 ratio to receive maraviroc once daily, maraviroc twice daily, or placebo) would provide more than 95% power to detect a treatment difference in the HIV-1 RNA level of 0.5 log10 copies per milliliter between each maraviroc group and the placebo group in each study. The relative efficacy of the two different maraviroc doses was not formally evaluated.
Genotypic, phenotypic, and overall susceptibility scores at screening were calculated to assess the number of potentially active agents in the optimized background therapy. Scores were assigned with the use of a binary system in which each drug was coded as 1 for full susceptibility and 0 for reduced susceptibility, based on genotypic or phenotypic data. The overall susceptibility score was based on the net assessment from the resistance tests, which was derived from both genotypic and phenotypic susceptibility data with the use of a proprietary algorithm, except that for enfuvirtide, the overall susceptibility score was based solely on the genotype. A drug was classified as active if the resistance test was unavailable at the time of screening.
Efficacy data were analyzed for all patients who had undergone randomization and received at least one dose of the assigned study drug. An analysis-of-covariance model was used, with the viral load at screening, use or nonuse of enfuvirtide, and study group as the main covariables. For the primary efficacy analysis, if the study drug was discontinued for any reason at or before week 48, the change from baseline was recorded as zero. The change from baseline was also recorded as zero if baseline data were missing or there was no assessment of HIV-1 RNA level at a specific time point. An HIV-1 RNA level of less than 50 copies per milliliter was designated as 49 copies per milliliter for the analyses. Missing values were classified as nonresponses. A change in the CD4 cell count from baseline was analyzed with an analysis-of-covariance model, with the CD4 cell count at screening, use or nonuse of enfuvirtide, and study group as the covariables. For the analysis of the change in the CD4 cell count from baseline, the last-observation-carried-forward method was used.
Safety data were analyzed for all patients who underwent randomization and received at least one dose of the assigned study drug. Adverse events were assessed until 7 days after discontinuation of the study drug or until the time from the end of therapy in the blinded study to the start of therapy with open-label antiretroviral drugs, whichever was shorter. Serious adverse events were assessed until 28 days after discontinuation of the study drug. Serious, treatment-related adverse events were reported regardless of whether the study drug was discontinued. All reported P values are two-sided and have not been adjusted for multiple comparisons.
Results
Study Population
Of the 3244 patients screened for the two studies between November 2004 and March 2006, 61% had R5 HIV-1 only, as shown by a coreceptor-tropism assay. Of these patients, 1075 underwent randomization at 239 study sites, with more patients enrolled in MOTIVATE 1 (601) than in MOTIVATE 2 (474); 1049 patients received at least one dose of the study drug (Figure 1Figure 1
Screening, Randomization, and Completion of Treatment.).The demographic and baseline characteristics of the patients were similar between the two studies and were balanced among the study groups, with mean HIV-1 RNA levels of 4.85 and 4.86 log10 copies per milliliter and median CD4 counts of 159 and 176 cells per cubic millimeter in MOTIVATE 1 and MOTIVATE 2, respectively (Table 1Table 1
Baseline Characteristics of the Patients.). Of the 1049 patients who received at least one dose of the study drug, 766 (73%), 651 (62%), and 708 (67%) had genotypic, phenotypic, and overall susceptibility scores of 2 or less, respectively. Approximately 57% of patients had CD4 counts of less then 200 cells per cubic millimeter. A total of 82% of patients were taking antiretroviral drugs at study entry; 18% had not taken antiretroviral drugs within 7 days before study entry.Discontinuation of Treatment
In the two studies combined, a total of 143 (68%) of the patients taking placebo discontinued treatment by week 48, as compared with 162 (39%) of those taking maraviroc once daily and 148 (35%) of those taking maraviroc twice daily (Figure 1). The most common reason for discontinuation was lack of efficacy in the opinion of the site investigator, based on protocol-defined treatment failure. Discontinuation was related to adverse events in 11 patients (5%) taking placebo as compared with 20 (5%) taking maraviroc once daily and 19 (4%) taking maraviroc twice daily. The median duration of treatment was 144 days in the placebo group, as compared with 335 and 336 days in the maraviroc once-daily and twice-daily groups, respectively.
Efficacy
The primary end-point results were similar between the two studies (Table 2Table 2
Efficacy at 48 Weeks.). In MOTIVATE 1, the mean change in plasma levels of HIV-1 RNA from baseline at 48 weeks was –0.80 log10 copies per milliliter in the placebo group versus –1.66 log10 copies per milliliter in the group that received maraviroc once daily (difference, –0.85; 97.5% confidence interval [CI], –1.22 to –0.49) and –1.82 log10 copies per milliliter in the group that received maraviroc twice daily (difference, –1.02; 97.5% CI, –1.39 to –0.66). The corresponding figures for MOTIVATE 2 were –0.76 log10 copies per milliliter in the placebo group versus –1.72 log10 copies per milliliter in the group that received maraviroc once daily (difference, –0.96; 97.5% CI, –1.38 to –0.54) and –1.87 log10 copies per milliliter in the group that received maraviroc twice daily (difference, –1.11; 97.5% CI, –1.52 to –0.70).In the pooled analysis, the mean change from baseline to week 48 in plasma HIV-1 RNA levels was –0.79 log10 copies per milliliter in the placebo group as compared with –1.68 log10 copies per milliliter in the group that received maraviroc once daily (difference, –0.90; 97.5% CI, –1.17 to –0.62) and –1.84 log10 copies per milliliter in the group that received maraviroc twice daily (difference, –1.05; 97.5% CI, –1.33 to –0.78) (Table 2).
For each of the secondary virologic end points, including the rates of virologic suppression to less than 400 and less than 50 copies per milliliter over the 48-week period (Table 2 and Figure 2AFigure 2
Treatment Responses at 48 Weeks.), the response with maraviroc once daily and twice daily was also significantly better than with placebo: for suppression to less than 400 copies per milliliter, the response rate was 51% (maraviroc once daily) and 57% (maraviroc twice daily) versus 22% (placebo) in MOTIVATE 1 and 53% and 55% versus 23%, respectively, in MOTIVATE 2; for suppression to less than 50 copies per milliliter, the respective response rates were 42% and 47% versus 16% in MOTIVATE 1 and 45% and 45% versus 18% in MOTIVATE 2 (P<0.001 for pairwise comparisons). Detailed subgroup analyses are presented by Fätkenheuer et al. in this issue of the Journal. 27 The time to treatment failure in the two studies combined was similar in the two maraviroc groups and was significantly longer than in the placebo group (P<0.001 for pairwise comparisons) (Figure 2B). In the two studies combined, the increase in the CD4 cell count from baseline to week 48 was similar in the two maraviroc groups and significantly greater than the increase in the placebo group (P<0.001 for pairwise comparisons) (Table 2 and Figure 2C). In MOTIVATE 1, the mean increases in the CD4 count in the group that received maraviroc once daily and in the group that received maraviroc twice daily were 113 and 122 cells per cubic millimeter, respectively, as compared with 54 cells per cubic millimeter in the placebo group; in MOTIVATE 2, the mean increases were 122 and 128 cells per cubic millimeter in the groups receiving maraviroc once daily and twice daily, respectively, as compared with 69 cells per cubic millimeter in the placebo group.
Safety
There were no clinically relevant differences in safety events between the two studies; therefore, analyses of pooled data are presented. Safety data are unadjusted for the duration of therapy. The higher rate of study-drug discontinuation in the placebo group means that these patients spent less time receiving the study drug than did patients in the maraviroc groups: 111 patient-years for placebo versus 300 patient-years for maraviroc once daily and 309 patient-years for maraviroc twice daily.
The rate of adverse events from any cause was lower with placebo (85%) than with maraviroc once daily (91%) or twice daily (92%) (P=0.01); there were no significant differences in the rates of treatment-related adverse events (Table 3Table 3
Adverse Events (MOTIVATE 1 and MOTIVATE 2 Study Populations Combined).). Post hoc analyses, unadjusted for treatment duration or multiple testing, showed that for grade 2, 3, or 4 adverse events occurring in 5% or more of patients, the only event rates that differed significantly among the study groups were those for fever (4% in the placebo group, 2% in the group that received maraviroc once daily, and 6% in the group that received maraviroc twice daily; P=0.04) and headache (6%, 5%, and 2%, respectively; P=0.03). Discontinuation because of adverse events related to the study treatment was uncommon, and the discontinuation rate was the same in the three groups (placebo, 6 of 209 patients [3%]; maraviroc once daily, 12 of 414 [3%]; and maraviroc twice daily, 13 of 426 [3%]).Rates of serious adverse events were similar among the treatment groups (placebo, 18%; maraviroc once daily, 18%; and maraviroc twice daily, 21%). A total of 17 patients died during treatment, with no significant differences among the three groups (placebo, 2 patients [1%], 1 of whom had received open-label maraviroc; maraviroc once daily, 6 [1%]; and maraviroc twice daily, 9 [2%]); none of the deaths were considered to be treatment-related. There were 74 category C events in 68 patients during treatment, with no significant differences among groups, except for esophageal candidiasis (in 2 patients in the placebo group, 12 in the group that received maraviroc once daily, and 3 in the group that received maraviroc twice daily, P=0.04) (Table 3). Five of the 12 cancers identified as category C events (including 2 of 6 lymphomas) occurred in patients receiving placebo.
The incidence of laboratory-test abnormalities was similar among the study groups, with no significant differences in the incidence of grade 3 or grade 4 abnormalities (see the Supplementary Appendix, available with the full text of this article at www.nejm.org). In the combined placebo groups, approximately 3% of patients had grade 3 or grade 4 increases in levels of aspartate aminotransferase or alanine aminotransferase, as compared with approximately 3 to 4% in the maraviroc groups, without adjustment for the duration of therapy (Table 3). There were no significant differences in the incidence of hepatic abnormalities except for a grade 1 elevation in the aspartate aminotransferase level (37% in the placebo group, 31% in the group that received maraviroc once daily, and 26% in the group that received maraviroc twice daily) and a grade 2 elevation in the alanine aminotransferase level (7%, 5%, and 10%, respectively; P=0.02 for both comparisons for all three groups) (see the Supplementary Appendix).
Discussion
These primary analyses of two ongoing phase 3 studies show that in previously treated patients infected with R5 HIV-1 only (as shown by a coreceptor-tropism assay) who are receiving optimized background therapy, the addition of maraviroc, as compared with placebo, is associated with a significantly greater reduction in the level of HIV-1 RNA and a greater increase in the CD4 cell count. The efficacy of maraviroc over placebo was further supported by the finding that 42 to 47% of patients taking maraviroc had HIV-1 RNA levels of less than 50 copies per milliliter at 48 weeks, as compared with 16% and 18% of those taking placebo.
Although the short-term efficacy of maraviroc was first shown in two phase 2 monotherapy studies in patients infected with R5 HIV-1,17 the MOTIVATE studies show that longer-term efficacy can be achieved by blocking a host protein, rather than a viral protein, with a small-molecule CCR5 coreceptor antagonist taken orally. These results are similar to those reported in studies evaluating other new drugs that target HIV directly28-33 and show that antiretroviral agents that target host and viral proteins can be used together to achieve virologic suppression in previously treated patients with HIV-1 infection. These results also support current antiretroviral treatment guidelines that recommend a new regimen with two (or preferably three) fully active agents from multiple drug classes for previously treated patients.4
The virologic response rates in the placebo groups in the current studies were notably higher than those seen at 48 weeks in the control groups of similarly designed studies — for example, the T-20 versus Optimized Background Regimen Only studies (TORO) involving patients with extensive previous treatment (HIV-1 RNA, <50 copies per milliliter overall in 17% vs. 8% of patients, respectively).31 This result is probably due to improvements in the drugs available to construct an optimized background regimen, including the use of enfuvirtide itself as part of the regimen in the MOTIVATE studies. In the recently completed studies of raltegravir — Blocking Integrase in Treatment Experienced Patients with a Novel Compound against HIV, Merck (BENCHMRK) — that allowed use of darunavir, even higher response rates (31 to 35%) were achieved in the placebo groups.32,33 The DUET studies of etravirine that mandated use of darunavir resulted in a response rate of 40% in the placebo groups.29,30 In the MOTIVATE studies, investigational agents (e.g., darunavir, etravirine, and raltegravir) were not permitted because no information on drug–drug interactions was available at the time, and only 15% of patients received tipranavir. Given the current availability of these newer antiretroviral drugs, combination regimens with maraviroc could be even more effective.
Treatment-related adverse events, study-drug discontinuation related to adverse events, AIDS-defining events, and deaths did not differ significantly across the three study groups, with the exception of esophageal candidiasis, which was more common in the group that received maraviroc once daily than in the placebo group or the group that received maraviroc twice daily. However, this difference must be interpreted cautiously, since the analysis was post hoc and was not adjusted for the duration of treatment exposure or for multiple testing. There were no significant differences between the maraviroc groups and the placebo group with respect to severe hepatotoxic effects, lymphoma, or other cancers, as reported in prior studies of other CCR5 antagonists.34,35 Given the relatively limited clinical experience with maraviroc to date, careful, longer-term safety monitoring would be prudent.
In general, studies of people with the CCR5 delta32 deletion show some immunologic effects. For example, the CCR5 delta32 mutation is associated with fewer signs and symptoms of rheumatoid arthritis36 but is also associated with more severe infection and increased mortality from West Nile virus in certain groups of patients.37 There are also data indicating that this host genetic deletion is associated with fewer cancers in patients with HIV infection.38 A congenital absence of CCR5 receptors, however, may not be equivalent to blocking of the CCR5 receptor with a small-molecule inhibitor; this again underscores the need for careful, longer-term safety monitoring is warranted.
These studies have several limitations. Although they were conducted on three continents, only about 10% of enrollees were women and less than 20% were nonwhite, which means that the generalizability of the results to other populations may be limited. The coreceptor-tropism assay used may not detect minority populations of X4 virus at baseline; the virus may emerge either before or during CCR5-antagonist therapy and may ultimately lead to reduced virologic responses. An enhanced tropism assay that better detects minority viral populations is now available.39 Use of newer antiretroviral drugs in the study regimens was limited (tipranavir) or prohibited (darunavir, etravirine, and raltegravir) because of the lack of data on drug–drug interactions with maraviroc or lack of availability of these investigational agents at the time. Safety comparisons were conducted post hoc and were not adjusted for treatment duration and multiple comparisons. Finally, although maraviroc, as compared with placebo, had superior virologic activity and resulted in higher CD4 cell counts with a similar safety profile in these 48-week studies, further follow-up is required to assess longer-term virologic and immunologic responses and drug-related side effects.
In summary, the results of these studies show that in previously treated patients with R5 HIV-1 infection only (as shown by a coreceptor-tropism assay), maraviroc, together with an antiretroviral regimen optimized on the basis of treatment history and drug-resistance testing, is effective and generally tolerated for at least 48 weeks.
MOTIVATE 1 and MOTIVATE 2 were sponsored by Pfizer Global Research and Development and were supported by Pfizer and by a grant from the National Institutes of Health (AI-51966, to Dr. Gulick). Assistance with manuscript preparation, funded by Pfizer, was provided by Health Interactions (London).
Dr. Gulick reports receiving consulting fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram, Pfizer, Schering-Plough, Tibotec, Virco, and ViroStatics and grant support from Boehringer Ingelheim, Gilead, Merck, Pfizer, Schering-Plough, and Tibotec. Dr. Lalezari reports receiving consulting and lecture fees from Pfizer. Dr. Goodrich and Ms. Ridgway report being employees of Pfizer, the study sponsor. Dr. Clumeck reports receiving consulting fees from Abbott, Gilead, Merck, and Pfizer. Dr. DeJesus reports receiving consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, and GlaxoSmithKline, lecture fees from Gilead, GlaxoSmithKline, and Merck, and grant support from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, Schering-Plough, and Tibotec. Dr. Horban reports receiving consulting fees from Janssen. Dr. Nadler reports holding equity ownership and stock options in Gilead. Dr. Clotet reports receiving consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck, Pfizer, Roche, and Siemens, lecture fees from Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche, and grant support from Merck and Pfizer. Dr. Wohlfeiler reports receiving consulting and lecture fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Monogram, Pfizer, and Tibotec and lecture fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Monogram, and Tibotec. Dr. McHale reports being previously employed by Pfizer and holding equity ownership and stock options in Pfizer. Mr. Sullivan and Drs. Felstead, Dunne, van der Ryst, and Mayer report being employees of Pfizer and holding equity ownership and stock options in Pfizer. No other potential conflict of interest relevant to this article was reported.
We thank the study participants as well as the study investigators and site staff at the 239 participating study sites (for a complete list of the investigators, site staff, and study sites, see the Supplementary Appendix).
Source Information
From Weill–Cornell Medical College, New York (R.M.G.); Quest Clinical Research and Mount Zion Hospital of the University of California, San Francisco, San Francisco (J.L.); Pfizer Global Research and Development, New London, CT (J.G., M.W.D., H.M.); Centre Hospitalier Universitaire St-Pierre, Brussels (N.C.); Orlando Immunology Center, Orlando, FL (E.D.); Wojewodzki Szpital Zakazny, Warsaw, Poland (A.H.); University of South Florida, College of Medicine, Tampa (J.N.); Fundació Irsicaixa and Hospital Universitari Germans Trias i Pujol, Badalona, Spain (B.C.); Venhälsan, Karolinska University Hospital, Stockholm (A.K.); Wohlfeiler, Piperato, and Associates, North Miami Beach, FL (M.W.); New York (J.B.M.); and Pfizer Global Research and Development, Sandwich, United Kingdom (M.M., J.S., C.R., S.F., E.R.).
Address reprint requests to Dr. Gulick at Weill–Cornell Medical College, Box 566, 525 E. 68th St., New York, NY 10065, or at rgulick@med.cornell.edu.
The members of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 study teams are listed in the Supplementary Appendix, available with the full text of this article at www.nejm.org.
- References
References
1
AIDSinfo. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, MD: Department of Health and Human Services, October 10, 2006. (Accessed September 9, 2008, at http://aidsinfo.nih.gov/Guidelines/ArchivedGuidelines.aspx.)
2
Phillips AN ,Dunn D ,Sabin C , et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005;19:487-494
CrossRef | Web of Science | Medline3
Mocroft A ,Devereux H ,Kinloch-de-Loes S , et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS 2000;14:1545-1552
CrossRef | Web of Science | Medline4
AIDSinfo. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Rockville, MD: Department of Health and Human Services, January 29, 2008. (Accessed September 9, 2008, at http://aidsinfo.nih.gov/guidelines.)
5
Liu R ,Paxton WA ,Choe S , et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377
CrossRef | Web of Science | Medline6
Dean M ,Carrington M ,Winkler C , et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-1862[Erratum, Science 1996;274:1069.]
CrossRef | Web of Science | Medline7
Huang Y ,Paxton WA ,Wolinsky SM , et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243
CrossRef | Web of Science | Medline8
de Roda Husman AM ,Koot M ,Cornelissen M , et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127:882-890
Web of Science | Medline9
Connor RI ,Sheridan KE ,Ceradini D ,Choe S ,Landau NR . Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628
CrossRef | Web of Science | Medline10
Philpott SM . HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 2003;1:217-227
CrossRef | Web of Science | Medline11
Whitcomb JM, Huang W, Fransen S, et al. Analysis of baseline enfuvirtide (T20) susceptibility and co-receptor tropism in two phase III study populations. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003.
12
Melby T ,Despirito M ,Demasi R ,Heilek-Snyder G ,Greenberg ML ,Graham N . HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006;194:238-246
CrossRef | Web of Science | Medline13
Wilkin TJ ,Su Z ,Kuritzkes DR , et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007;44:591-595[Erratum, Clin Infect Dis 2007;44:1399.]
CrossRef | Web of Science | Medline14
Dorr P ,Westby M ,Dobbs S , et al. Maraviroc (UK-427,857): a potent, orally bioavailable, and selective small-molecule inhibitor of the chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-4732
CrossRef | Web of Science | Medline15
Westby M ,van der Ryst E . CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005;16:339-354
Medline16
Selzentry prescribing information. New York: Pfizer, 2007 (package insert).
17
Fatkenheuer G ,Pozniak AL ,Johnson MA , et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-1172
CrossRef | Web of Science | Medline18
Goodrich J, Saag M, van der Ryst E, et al. 48-Week safety and efficacy of maraviroc in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced patients infected with dual/mixed-tropic HIV-1. Presented at the 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, October 4–7, 2007.
19
Limoli K, Whitcomb J, Kiss L, et al. Technical validation defines the performance of Trofile–Monogram's HIV co-receptor tropism assay. Presented at the XVI International AIDS Conference, Toronto, August 13–18, 2006.
20
Whitcomb JM ,Huang W ,Fransen S , et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51:566-575
CrossRef | Web of Science | Medline21
Abel S ,Jenkins TM ,Whitlock LA ,Ridgway CE ,Muirhead GJ . Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65:Suppl 1:38-46
CrossRef | Web of Science | Medline22
Abel S ,Russell D ,Taylor-Worth RJ ,Ridgway CE ,Muirhead GJ . Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65:Suppl 1:27-37
CrossRef | Web of Science | Medline23
Lalezari JP ,Henry K ,O'Hearn M , et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185[Erratum, N Engl J Med 2003;349:1100.]
Full Text | Web of Science | Medline24
Lazzarin A ,Clotet B ,Cooper D , et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195
Full Text | Web of Science | Medline25
1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19
26
Regulatory Compliance Center. Division of AIDS: table for grading severity of adult adverse experiences 1992. (Accessed September 9, 2008, at http://rcc.tech-res.com/tox_tables.htm.)
27
Fatkenheuer G ,Nelson M ,Lazzarin A , et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359:1442-1455
Full Text | Web of Science | Medline28
Clotet B ,Bellos N ,Molina JM , et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178[Erratum, Lancet 2008;371:116.]
CrossRef | Web of Science | Medline29
Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 3–6, 2008.
30
Johnson M, Campbell T, Clotet B, et al. DUET-2: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 3–6, 2008.
31
Nelson M ,Arasteh K ,Clotet B , et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-412
CrossRef | Web of Science | Medline32
Steigbigel RT ,Cooper DA ,Kumar PN , et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-354
Full Text | Web of Science | Medline33
Cooper DA ,Steigbigel RT ,Gatell JM , et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infeciton. N Engl J Med 2008;359:355-365
Full Text | Web of Science | Medline34
Nichols WG ,Steel HM ,Bonny T , et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008;52:858-865
CrossRef | Web of Science | Medline35
Gulick RM ,Su Z ,Flexner C , et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007;196:304-312
CrossRef | Web of Science | Medline36
Garred P ,Madsen HO ,Petersen J , et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998;25:1462-1465
Web of Science | Medline37
Glass WG ,McDermott DH ,Lim JK , et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35-40
CrossRef | Web of Science | Medline38
Dean M ,Jacobson LP ,McFarlane G , et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999;59:3561-3564
Web of Science | Medline39
Trinh L, Han D, Huang W, et al. Technical validation of an enhanced sensitivity Trofile HIV co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Presented at the XVII International HIV Drug Resistance Workshop, Sitges, Spain, June 10–14, 2008.
- Citing Articles (163)
Citing Articles
1
Timothy J. Wilkin, Roy M. Gulick. (2012) CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities. Annual Review of Medicine 63:1, 81-93
CrossRef2
Renee M. Mosi, Virginia Anastassova, Jennifer Cox, Marilyn C. Darkes, Stefan R. Idzan, Jean Labrecque, Gloria Lau, Kim L. Nelson, Ketan Patel, Zefferino Santucci, Rebecca S.Y. Wong, Renato T. Skerlj, Gary J. Bridger, Dana Huskens, Dominique Schols, Simon P. Fricker. (2012) The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor. Biochemical Pharmacology 83:4, 472-479
CrossRef3
Renato T Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Ernest McEachern, Sanjay J. Danthi, Jonathan Langille, Curtis W Harwig, Duane Veale, Byron Carpenter, Tuya Ba, Michael Bey, Ian Baird, Trevor Wilson, Markus Metz, Ron MacFarland, Renee Mosi, Veronique Bodart, Rebecca Wong, Simon P. Fricker, Dana Huskens, Dominique Schols. (2012) Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication. ACS Medicinal Chemistry Letters120125111342009
CrossRef4
Jason B. Crawford, Gang Chen, Bryon Carpenter, Trevor Wilson, Jenny Ji, Renato T. Skerlj, Gary J. Bridger. (2012) Practical Convergent Laboratory-Scale Synthesis of a CCR5 Receptor Antagonist. Organic Process Research & Development 16:1, 109-116
CrossRef5
Christian Krebs, Christoph Fraune, Robin Schmidt-Haupt, Jan-Eric Turner, Ulf Panzer, Michael N. Quang, Andrea Tannapfel, Joachim Velden, Rolf A. Stahl, Ulrich O. Wenzel. (2012) CCR5 Deficiency Does Not Reduce Hypertensive End-Organ Damage in Mice. American Journal of Hypertension
CrossRef6
Jan-Christian Wasmuth, Jürgen Kurt Rockstroh, William David Hardy. (2012) Drug safety evaluation of maraviroc for the treatment of HIV infection. Expert Opinion on Drug Safety 11:1, 161-174
CrossRef7
Josephine Mauskopf, Anita J. Brogan, Sandra E. Talbird, Silas Martin. (2012) Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS 26:3, 355-364
CrossRef8
Caroline E. Sloan, Karen Champenois, Philippe Choisy, Elena Losina, Rochelle P. Walensky, Bruce R. Schackman, Faiza Ajana, Hugues Melliez, A.D. Paltiel, Kenneth A. Freedberg, Yazdan Yazdanpanah. (2012) Newer drugs and earlier treatment. AIDS 26:1, 45-56
CrossRef9
Ivona Pandrea, Alan L. Landay. 2012. Implications for Therapy. , 81-132.
CrossRef10
Jean-Michel Molina, Anthony LaMarca, Jaime Andrade-Villanueva, Bonaventura Clotet, Nathan Clumeck, Ya-Pei Liu, Lijie Zhong, Nicolas Margot, Andrew K Cheng, Steven L Chuck. (2012) Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. The Lancet Infectious Diseases 12:1, 27-35
CrossRef11
Belete Ayele Desimmie, Rik Schrijvers, Zeger Debyser. (2012) Elvitegravir: a once daily alternative to raltegravir. The Lancet Infectious Diseases 12:1, 3-5
CrossRef12
Barbara H. McGovern, Mark S. Sulkowski, Richard K. Sterling. 2012. HIV Co-Infection Drug Toxicity. , 683-699.
CrossRef13
Paola Vitiello, Daniel Brudney, Malcolm MacCartney, Ana Garcia, Colette Smith, Neal Marshall, Margaret Johnson, Anna Maria Geretti. (2012) Responses to Switching to Maraviroc-Based Antiretroviral Therapy in Treated Patients with Suppressed Plasma HIV-1-RNA Load. Intervirology 55:2, 172-178
CrossRef14
Saleta Sierra, Hauke Walter. (2012) Targets for Inhibition of HIV Replication: Entry, Enzyme Action, Release and Maturation. Intervirology 55:2, 84-97
CrossRef15
Bethany L. Morris, Callie A. Scott, Timothy J. Wilkin, Paul E. Sax, Roy M. Gulick, Kenneth A. Freedberg, Bruce R. Schackman. (2012) Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. HIV Clinical Trials 13:1, 1-10
CrossRef16
Michael Ohl, Brian Lund, Pamela S. Belperio, Matthew Bidwell Goetz, David Rimland, Kelly Richardson, Amy Justice, Eli Perencevich, Mary Vaughan-Sarrazin. (2011) Rural Residence and Adoption of a Novel HIV Therapy in a National, Equal-Access Healthcare System. AIDS and Behavior
CrossRef17
P. Rieder, B. Joos, A. U. Scherrer, H. Kuster, D. Braun, C. Grube, B. Niederost, C. Leemann, S. Gianella, K. J. Metzner, J. Boni, R. Weber, H. F. Gunthard. (2011) Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. Clinical Infectious Diseases 53:12, 1271-1279
CrossRef18
C. Okoli, M. Siccardi, S. Thomas-William, N. Dufty, K. Khonyongwa, J. Ainsworth, J. Watson, R. Cook, K. Gandhi, G. Hickinbottom, A. Owen, S. Taylor. (2011) Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. Journal of Antimicrobial Chemotherapy
CrossRef19
Ildefonso Pulido, Kawthar Machmach, María C. Romero-Sánchez, Miguel Genebat, Gema Mendez-Lagares, Ezequiel Ruiz-Mateos, Manuel Leal. (2011) T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. Journal of Infection
CrossRef20
Daniel R Kuritzkes. (2011) Drug resistance in HIV-1. Current Opinion in Virology 1:6, 582-589
CrossRef21
Emmanuel González-Ortega, Ester Ballana, Roger Badia, Bonaventura Clotet, José A. Esté. (2011) Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1. Antiviral Research 92:3, 479-483
CrossRef22
Renato Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Ernest McEachern, Jonathan Langille, Curtis Harwig, Duane Veale, Wen Yang, Tongshong Li, Yongbao Zhu, Michael Bey, Ian Baird, Michael Sartori, Markus Metz, Renee Mosi, Kim Nelson, Veronique Bodart, Rebecca Wong, Simon Fricker, Ron Mac Farland, Dana Huskens, Dominique Schols. (2011) Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. Bioorganic & Medicinal Chemistry Letters 21:23, 6950-6954
CrossRef23
Félix Gutiérrez, Juan Carlos Rodríguez, Federico García, Eva Poveda. (2011) Tropismo del VIH. Técnicas disponibles y utilidad. Enfermedades Infecciosas y Microbiología Clínica 29, 45-50
CrossRef24
M Pichenot, S Deuffic-Burban, L Cuzin, Y Yazdanpanah. (2011) Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials. HIV Medicineno-no
CrossRef25
Jessica E. Taaffe, Steven E. Bosinger, Gregory Q. Del Prete, James G. Else, Sarah Ratcliffe, Christopher D. Ward, Thi Migone, Mirko Paiardini, Guido Silvestri. (2011) CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques. Journal of Medical Primatologyno-no
CrossRef26
Sheila Ruiz Ruiz, María Tasias Pitarch, Antonio Delegido Sánchez-Migallón, Enric Pedrol Clotet. (2011) Leishmaniasis recidivante en paciente con infección por VIH: un reto terapéutico. Enfermedades Infecciosas y Microbiología Clínica
CrossRef27
C Verhofstede, D Brudney, J Reynaerts, D Vaira, K Fransen, A De Bel, C Seguin-Devaux, S De Wit, L Vandekerckhove, A-M Geretti. (2011) Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Medicine 12:9, 544-552
CrossRef28
L. C. Swenson, T. Mo, W. W. Y. Dong, X. Zhong, C. K. Woods, A. Thielen, M. A. Jensen, D. J. H. F. Knapp, D. Chapman, S. Portsmouth, M. Lewis, I. James, J. Heera, H. Valdez, P. R. Harrigan. (2011) Deep V3 Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc. Clinical Infectious Diseases 53:7, 732-742
CrossRef29
Arkaitz Imaz, Josep M Llibre, Esteban Ribera, Bonaventura Clotet, Daniel Podzamczer. (2011) The Role of Inactive Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Salvage Therapy for Drug-Resistant HIV-1 Infection in the Era of New Classes and New Generation Antiretrovirals. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:2, e46-e48
CrossRef30
L. C. Swenson, P. R. Harrigan. (2011) Reply to Abbate et al. Journal of Infectious Diseases 204:6, 973-974
CrossRef31
J. Symons, L. Vandekerckhove, R. Paredes, C. Verhofstede, R. Bellido, E. Demecheleer, P. M. van Ham, S. F. L. van Lelyveld, A. J. Stam, D. van Versendaal, M. Nijhuis, A. M. J. Wensing. (2011) Impact of triplicate testing on genotypic HIV-1 tropism prediction in routine clinical practice. Clinical Microbiology and Infectionno-no
CrossRef32
Jayaram R. Tagat, Julie M. Strizki, Lisa M. Dunkle. 2011. Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection. , 137-147.
CrossRef33
Koen Andries, Ann Debunne, Thomas N. Kakuda, Michael Kukla, Ruud Leemans, Johan Vingerhoets, Brian Woodfall, Marie-Pierre de Béthune. 2011. Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients. , 71-84.
CrossRef34
Emmanuel Gonzalez, Ester Ballana, Bonaventura Clotet, José A. Esté. (2011) Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS 25:13, 1557-1583
CrossRef35
Jorge Parra, Joaquín Portilla, Federico Pulido, Rainel Sánchez-de la Rosa, Carlos Alonso-Villaverde, Juan Berenguer, José L. Blanco, Pere Domingo, Fernando Dronda, Carlos Galera, Félix Gutiérrez, José M. Kindelán, Hernando Knobel, Manuel Leal, Jose López-Aldeguer, Ana Mariño, Celia Miralles, José Moltó, Enrique Ortega, José A. Oteo. (2011) Clinical Utility of Maraviroc. Clinical Drug Investigation 31:8, 527-542
CrossRef36
José R. Santos, Josep M. Llibre, Pere Domingo, Arkaitz Imaz, Elena Ferrer, Daniel Podzamczer, Isabel Bravo, Esteban Ribera, Sebastià Videla, Bonaventura Clotet. (2011) Short Communication: High Effectiveness of Etravirine in Routine Clinical Practice in Treatment-Experienced HIV Type 1-Infected Patients. AIDS Research and Human Retroviruses 27:7, 713-717
CrossRef37
Matthew Grant, Rafik Samuel, Robert L. Bettiker, Byungse Suh. (2011) Antiretroviral therapy 2010 update: Current practices and controversies. Archives of Pharmacal Research 34:7, 1045-1053
CrossRef38
S. Sahali, G. Carcelain, C. Goujard, J.-F. Delfraissy, J. Ghosn. (2011) Stratégies de restauration immunitaire chez les patients infectés par le virus de l’immunodéficience humaine. La Revue de Médecine Interne 32:7, 425-431
CrossRef39
Fernando Lozano, Pere Domingo. (2011) Tratamiento antirretroviral de la infección por el VIH. Enfermedades Infecciosas y Microbiología Clínica 29:6, 455-465
CrossRef40
Lee Adam Wheeler, Radiana Trifonova, Vladimir Vrbanac, Emre Basar, Shannon McKernan, Zhan Xu, Edward Seung, Maud Deruaz, Tim Dudek, Jon Ivar Einarsson, Linda Yang, Todd M. Allen, Andrew D. Luster, Andrew M. Tager, Derek M. Dykxhoorn, Judy Lieberman. (2011) Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. Journal of Clinical Investigation 121:6, 2401-2412
CrossRef41
S. Di Giambenedetto, M. Prosperi, I. Fanti, B. Bruzzone, S. Paolucci, G. Penco, G. Meini, A. Di Biagio, E. Paolini, V. Micheli, P. Meraviglia, P. Castelli, P. Corsi, A. Gonnelli, M. Fabbiani, M. Zazzi, A. De Luca, . (2011) Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. Clinical Microbiology and Infectionno-no
CrossRef42
Paolo Troia-Cancio, David M Asmuth. (2011) Lessons from maraviroc clinical trials. Expert Review of Anti-infective Therapy 9:6, 649-651
CrossRef43
José A. Esté. 2011. Inhibition of HIV Entry. , 29-50.
CrossRef44
Thomas J. Schall, Amanda E. I. Proudfoot. (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nature Reviews Immunology 11:5, 355-363
CrossRef45
Mas Chaponda, Munir Pirmohamed. (2011) Hypersensitivity reactions to HIV therapy. British Journal of Clinical Pharmacology 71:5, 659-671
CrossRef46
Alexandra U Scherrer, Viktor von Wyl, Jürg Böni, Sabine Yerly, Thomas Klimkait, Philippe Bürgisser, Christian Garzoni, Bernard Hirschel, Matthias Cavassini, Manuel Battegay, Pietro L Vernazza, Enos Bernasconi, Bruno Ledergerber, Huldrych F Günthard. (2011) Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes 57:1, 24-31
CrossRef47
I. Abbate, G. Rozera, C. Tommasi, A. Bruselles, B. Bartolini, G. Chillemi, E. Nicastri, P. Narciso, G. Ippolito, M. R. Capobianchi. (2011) Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clinical Microbiology and Infection 17:5, 725-731
CrossRef48
D J Dairaghi, P Zhang, Y Wang, L C Seitz, D A Johnson, S Miao, L S Ertl, Y Zeng, J P Powers, A M Pennell, P Bekker, T J Schall, J C Jaen. (2011) Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose. Clinical Pharmacology & Therapeutics 89:5, 726-734
CrossRef49
LPR Vandekerckhove, AMJ Wensing, R Kaiser, F Brun-Vézinet, B Clotet, A De Luca, S Dressler, F Garcia, AM Geretti, T Klimkait, K Korn, B Masquelier, CF Perno, JM Schapiro, V Soriano, A Sönnerborg, A-M Vandamme, C Verhofstede, H Walter, M Zazzi, CAB Boucher. (2011) European guidelines on the clinical management of HIV-1 tropism testing. The Lancet Infectious Diseases 11:5, 394-407
CrossRef50
Zygimantas C Alsauskas, Raj Kiran Medapalli, Michael J Ross. (2011) Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opinion on Pharmacotherapy 12:5, 691-704
CrossRef51
Diana Edo-Matas, Karel A. van Dort, Laurentia C. Setiawan, Hanneke Schuitemaker, Neeltje A. Kootstra. (2011) Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. Virology 412:2, 269-277
CrossRef52
Renato Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Jonathan Langille, Maria Di Fluri, David Bogucki, Wen Yang, Tongshuang Li, Letian Wang, Susan Nan, Ian Baird, Markus Metz, Marilyn Darkes, Jean Labrecque, Gloria Lau, Simon Fricker, Dana Huskens, Dominique Schols. (2011) Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. Bioorganic & Medicinal Chemistry Letters 21:8, 2450-2455
CrossRef53
J. Symons, S. F. L. van Lelyveld, A. I. M. Hoepelman, P. M. van Ham, D. de Jong, A. M. J. Wensing, M. Nijhuis. (2011) Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. Journal of Antimicrobial Chemotherapy 66:4, 890-895
CrossRef54
Renato Skerlj, Gary Bridger, Ernest McEachern, Curtis Harwig, Chris Smith, Alan Kaller, Duane Veale, Helen Yee, Krystyna Skupinska, Rossana Wauthy, Letian Wang, Ian Baird, Yongbao Zhu, Kate Burrage, Wen Yang, Michael Sartori, Dana Huskens, Erik De Clercq, Dominique Schols. (2011) Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. Bioorganic & Medicinal Chemistry Letters 21:5, 1414-1418
CrossRef55
L. J. Waters, A. T. Scourfield, M. Marcano, B. G. Gazzard, M. Bower, M. Nelson, J. Stebbing. (2011) The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy. Clinical Infectious Diseases 52:5, 671-673
CrossRef56
Olga Latinovic, Marvin Reitz, Nhut M. Le, James S. Foulke, Gerd Fätkenheuer, Clara Lehmann, Robert R. Redfield, Alonso Heredia. (2011) CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells. Virology 411:1, 32-40
CrossRef57
Brianna L Norton, Charles B Hicks. (2011) Maraviroc: the first chemokine coreceptor 5 inhibitor. Future Virology 6:3, 283-294
CrossRef58
Nicola Gianotti, Laura Galli, Maurizio Zazzi, Valeria Ghisetti, Stefano Bonora, Valeria Micheli, Paola Meraviglia, Paola Corsi, Bianca Bruzzone, Stefano Menzo, Simona Di Giambenedetto, Andrea De Luca, Gaetano Filice, Giovanni Penco, Antonella Castagna, . (2011) No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. Journal of Medical Virology 83:3, 391-398
CrossRef59
S. S. Virani, V. Nambi, R. Hoogeveen, B. A. Wasserman, J. Coresh, F. Gonzalez, L. E. Chambless, T. H. Mosley, E. Boerwinkle, C. M. Ballantyne. (2011) Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. European Heart Journal 32:4, 459-468
CrossRef60
A. Imaz, J. M. Llibre, M. Mora, G. Mateo, A. Camacho, J. R. Blanco, A. Curran, J. R. Santos, E. Caballero, I. Bravo, F. Gaya, P. Domingo, A. Rivero, V. Falco, B. Clotet, E. Ribera. (2011) Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. Journal of Antimicrobial Chemotherapy 66:2, 358-362
CrossRef61
L. C. Swenson, T. Mo, W. W. Y. Dong, X. Zhong, C. K. Woods, M. A. Jensen, A. Thielen, D. Chapman, M. Lewis, I. James, J. Heera, H. Valdez, P. R. Harrigan. (2011) Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients. Journal of Infectious Diseases 203:2, 237-245
CrossRef62
D. R. Kuritzkes. (2011) Genotypic Tests for Determining Coreceptor Usage of HIV-1. Journal of Infectious Diseases 203:2, 146-148
CrossRef63
S. Ylä-Herttuala, J. F. Bentzon, M. Daemen, E. Falk, H. M. Garcia-Garcia, J. Herrmann, I. Hoefer, J. W. Jukema, R. Krams, B. R. Kwak, N. Marx, M. Naruszewicz, A. Newby, G. Pasterkamp, P. W. J. C. Serruys, J. Waltenberger, C. Weber, L. Tokgözoglu. (2011) Stabilisation of atherosclerotic plaques. Thrombosis and Haemostasis 106:1, 1-19
CrossRef64
M. Lartey, K. Torpey, J.K. Aronson. 2011. Antiviral drugs. , 577-621.
CrossRef65
Mary Albrecht, A. Lisa Mukherjee, Camlin Tierney, Gene D. Morse, Carrie Dykes, Karin L. Klingman, Lisa M. Demeter. (2011) A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor–Based Regimens in Antiretroviral-Experienced HIV-Infected Individuals: Week 48 Results of the A5146 Study. HIV Clinical Trials 12:4, 201-214
CrossRef66
José Javier Rodríguez, Eduardo Seclén, Eva Poveda, Eduardo Varela, Benito Regueiro, Antonio Aguilera. (2011) Variabilidad en la determinación del tropismo viral del VIH utilizando diferentes algoritmos genotípicos de interpretación en pacientes VIH-1 infectados con subtipos B versus no-B. Enfermedades Infecciosas y Microbiología Clínica 29:1, 4-8
CrossRef67
I. Castillo Romera, A. Ais Larisgoitia, A.N. Trovato López, V. Escudero Villaplana, J.M. Bellón Cano, M. Sanjurjo Saéz. (2011) Indications for the use of next-generation antiretroviral drugs in current clinical practice. Farmacia Hospitalaria (English Edition) 35:1, 14-22
CrossRef68
(2011) Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans. Infection and Chemotherapy 43:2, 89
CrossRef69
Renato Skerlj, Gary Bridger, Ernie McEachern, Curtis Harwig, Chris Smith, Trevor Wilson, Duane Veale, Helen Yee, Jason Crawford, Krystyna Skupinska, Rossana Wauthy, Wen Yang, Yongbao Zhu, David Bogucki, Maria Di Fluri, Jonathon Langille, Dana Huskens, Erik De Clercq, Dominique Schols. (2011) Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication. Bioorganic & Medicinal Chemistry Letters 21:1, 262-266
CrossRef70
Wei Huang, Arne Frantzell, Jonathan Toma, Signe Fransen, Jeannette M. Whitcomb, Eric Stawiski, Christos J. Petropoulos. (2011) Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1. Virology 409:2, 308-318
CrossRef71
P Richard Harrigan, Anna Maria Geretti. (2011) Genotypic tropism testing: evidence-based or leap of faith?. AIDS 25:2, 257-264
CrossRef72
Timothy J Henrich, Athe M N Tsibris, Nicolas R P Lewine, Ioannis Konstantinidis, Kay E Leopold, Manish Sagar, Daniel R Kuritzkes. (2010) Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:4, 420-427
CrossRef73
Q. Hu, X. Huang, R. J. Shattock. (2010) C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors. Journal of General Virology 91:12, 2965-2973
CrossRef74
Mark A. Boyd, Andrew M. Hill. (2010) Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era. PharmacoEconomics 28, 17-34
CrossRef75
N. Gonzalez, M. Perez-Olmeda, E. Mateos, A. Cascajero, A. Alvarez, S. Spijkers, J. Garcia-Perez, S. Sanchez-Palomino, E. Ruiz-Mateos, M. Leal, J. Alcami. (2010) A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. Journal of Antimicrobial Chemotherapy 65:12, 2493-2501
CrossRef76
Santiago Moreno, Juan González, Ingrid Lekander, Belén Martí, Itziar Oyagüez, Rainel Sánchez-de la Rosa, Miguel Angel Casado. (2010) Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. Clinical Therapeutics 32:13, 2232-2245
CrossRef77
James H. Willig, Inmaculada Aban, Christa R. Nevin, Jiatao Ye, James L. Raper, James A. McKinnel, Lori L. DeLaitsch, Joseph M. Mrus, Guy R. De La Rosa, Michael J. Mugavero, Michael S. Saag. (2010) Darunavir Outcomes Study: Comparative Effectiveness of Virologic Suppression, Regimen Durability, and Discontinuation Reasons for Three-Class Experienced Patients at 48 Weeks. AIDS Research and Human Retroviruses 26:12, 1279-1285
CrossRef78
W David Hardy, Roy M Gulick, Howard Mayer, Gerd Fätkenheuer, Mark Nelson, Jayvant Heera, Natasa Rajicic, James Goodrich. (2010) Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:5, 558-564
CrossRef79
Iris Contreras-Hernandez, Debbie Becker, Jeremy Chancellor, Felicitas Kühne, Joaquin Mould-Quevedo, Gabriela Vega, Shalaka Marfatia. (2010) Cost-Effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-infected Individuals in Mexico. Value in Health 13:8, 903-914
CrossRef80
Michael M. Freeman, Michael S. Seaman, Sophia Rits-Volloch, Xinguo Hong, Chia-Ying Kao, David D. Ho, Bing Chen. (2010) Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody. Structure 18:12, 1632-1641
CrossRef81
Roy M Gulick. (2010) Antiretroviral Treatment 2010: Progress and Controversies. JAIDS Journal of Acquired Immune Deficiency Syndromes 55, S43-S48
CrossRef82
Ed Brewer, Tonya Felix, Phil Clarke, Alan Edgington, David Muirhead. (2010) An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857) in human plasma, urine and cerebrospinal fluid. Biomedical Chromatography 24:12, 1316-1323
CrossRef83
Jordan E Lake, Judith S Currier. (2010) Switching antiretroviral therapy to minimize metabolic complications. HIV Therapy 4:6, 693-711
CrossRef84
Rachel A McGovern, Alexander Thielen, Theresa Mo, Winnie Dong, Conan K Woods, Douglass Chapman, Marilyn Lewis, Ian James, Jayvant Heera, Hernan Valdez, P Richard Harrigan. (2010) Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 24:16, 2517-2525
CrossRef85
Reiko Tanaka, Yoshiaki Takahashi, Akira Kodama, Mineki Saito, Aftab A. Ansari, Yuetsu Tanaka. (2010) Suppression of CCR5-Tropic HIV Type 1 Infection by OX40 Stimulation via Enhanced Production of β-Chemokines. AIDS Research and Human Retroviruses 26:10, 1147-1154
CrossRef86
DS Fullerton, Mary Jane Watson, David Anderson, James Witek, Silas C Martin, Joseph M Mrus. (2010) Pharmacoeconomics of etravirine. Expert Review of Pharmacoeconomics & Outcomes Research 10:5, 485-495
CrossRef87
E. Fontas, I. Kousignian, C. Pradier, I. Poizot-Martin, C. Durier, L. Weiss, Y. Levy, D. Costagliola, , . (2010) IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort. Journal of Antimicrobial Chemotherapy 65:10, 2215-2223
CrossRef88
Babafemi Taiwo, Robert L. Murphy, Christine Katlama. (2010) Novel Antiretroviral Combinations in Treatment-Experienced Patients with HIV Infection. Drugs 70:13, 1629-1642
CrossRef89
Jonathan Toma, Jeannette M Whitcomb, Christos J Petropoulos, Wei Huang. (2010) Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors. AIDS 24:14, 2181-2186
CrossRef90
Lidia Gazzola, Camilla Tincati, Antonella d’Arminio Monforte. (2010) Noninfectious HIV-related comorbidities and HAART toxicities: choosing alternative antiretroviral strategies. HIV Therapy 4:5, 553-565
CrossRef91
Benedikt Simon, Katharina Grabmeier-Pfistershammer, Armin Rieger, Mario Sarcletti, Brigitte Schmied, Elisabeth Puchhammer-Stöckl. (2010) HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS 24:13, 2051-2058
CrossRef92
Timothy J Wilkin, Zhaohui Su, Amy Krambrink, Jianmin Long, Wayne Greaves, Robert Gross, Michael D Hughes, Charles Flexner, Paul R Skolnik, Eoin Coakley, Catherine Godfrey, Martin Hirsch, Daniel R Kuritzkes, Roy M Gulick. (2010) Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 54:5, 470-476
CrossRef93
Fabienne Caby, Nadia Valin, Anne Genevieve Marcelin, Luminata Schneider, Régis Andrade, Marguerite Guiguet, Roland Tubiana, Ana Canestri, Marc Antoine Valantin, Gilles Peytavin, Jérome Pacanowski, Laurence Morand-Joubert, Vincent Calvez, Pierre Marie Girard, Christine Katlama. (2010) Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. Scandinavian Journal of Infectious Diseases 42:6-7, 527-532
CrossRef94
Paul A Volberding, Steven G Deeks. (2010) Antiretroviral therapy and management of HIV infection. The Lancet 376:9734, 49-62
CrossRef95
Pierre Delobel, Stéphanie Raymond, Maud Mavigner, Michelle Cazabat, Muriel Alvarez, Bruno Marchou, Patrice Massip, Jacques Izopet. (2010) Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc. AIDS 24:9, 1382-1384
CrossRef96
Panel de expertos de Gesida, Plan Nacional sobre el Sida. (2010) Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010). Enfermedades Infecciosas y Microbiología Clínica 28:6, 362.e1-362.e91
CrossRef97
Caroline M. Perry. (2010) Maraviroc. Drugs 70:9, 1189-1213
CrossRef98
Sarah L. Pett, John Zaunders, Michelle Bailey, John Murray, Karen MacRae, Sean Emery, David A. Cooper, Anthony D. Kelleher. (2010) A Novel Chemokine-Receptor-5 (CCR5) Blocker, SCH532706, Has Differential Effects on CCR5 + CD4 + and CCR5 + CD8 + T Cell Numbers in Chronic HIV Infection. AIDS Research and Human Retroviruses 26:6, 653-661
CrossRef99
Herman G. Sprenger, Nienke Langebeek, Paul G.H. Mulder, Chris H.H. Ten Napel, Robert Vriesendorp, Andy I.M. Hoepelman, Jean-Claude Legrand, Peter P. Koopmans, Marjo E.E. Van Kasteren, Bert Bravenboer, Reinier W. Ten Kate, Paul H.P. Groeneveld, Tjip S. van der Werf, Elisabeth H. Gisolf, Clemens Richter. (2010) Abacavir/Lamivudine/Zidovudine Maintenance After Standard Induction in Antiretroviral Therapy-Naïve Patients: FREE Randomized Trial Interim Results. AIDS Patient Care and STDs 24:6, 361-366
CrossRef100
S. Moreno, J. Lopez Aldeguer, J. R. Arribas, P. Domingo, J. A. Iribarren, E. Ribera, A. Rivero, F. Pulido, . (2010) The future of antiretroviral therapy: challenges and needs. Journal of Antimicrobial Chemotherapy 65:5, 827-835
CrossRef101
Luke C Swenson, Richard Boehme, Alexander Thielen, Rachel A McGovern, P Richard Harrigan. (2010) Genotypic determination of HIV-1 tropism in the clinical setting. HIV Therapy 4:3, 293-303
CrossRef102
Anthony M Mills. (2010) The DUET trials: etravirine in the management of treatment-experienced HIV-1-infected patients. HIV Therapy 4:3, 265-280
CrossRef103
Robert A. Ogert, Yan Hou, Lei Ba, Lisa Wojcik, Ping Qiu, Nicholas Murgolo, Jose Duca, Lisa M. Dunkle, Robert Ralston, John A. Howe. (2010) Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 400:1, 145-155
CrossRef104
Manuel Battegay, Heiner C Bucher. (2010) Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy?. AIDS 24:7, 1057-1059
CrossRef105
Silvia Nozza, Laura Galli, Francesca Visco, Alessandro Soria, Filippo Canducci, Stefania Salpietro, Nicola Gianotti, Alba Bigoloni, Liviana Della Torre, Giuseppe Tambussi, Adriano Lazzarin, Antonella Castagna. (2010) Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 24:6, 924-928
CrossRef106
M. Armand-Ugon, G. Moncunill, E. Gonzalez, M. Mena, E. Ballana, B. Clotet, J. A. Este. (2010) Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. Journal of Antimicrobial Chemotherapy 65:3, 417-424
CrossRef107
Peter W Hunt. (2010) Th17, gut, and HIV: therapeutic implications. Current Opinion in HIV and AIDS 5:2, 189-193
CrossRef108
Krittaecho Siripassorn, Weerawat Manosuthi, Suthat Chottanapund, Aranya Pakdee, Siriwan Sabaitae, Wisit Prasithsirikul, Preecha Tunthanathip, Kiat Ruxrungtham. (2010) Effectiveness of Boosted Protease Inhibitor-Based Regimens in HIV Type 1-Infected Patients Who Experienced Virological Failure with NNRTI-Based Antiretroviral Therapy in a Resource-Limited Setting. AIDS Research and Human Retroviruses 26:2, 139-148
CrossRef109
Antonio DʼAvolio, Marco Simiele, Lorena Baietto, Marco Siccardi, Mauro Sciandra, Samantha Patanella, Stefano Bonora, Giovanni Di Perri. (2010) A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients. Therapeutic Drug Monitoring 32:1, 86-92
CrossRef110
Srinivasan Ramanathan, Samantha Abel, Sarah Tweedy, Steve West, James Hui, Brian P Kearney. (2010) Pharmacokinetic Interaction of Ritonavir-Boosted Elvitegravir and Maraviroc. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:2, 209-214
CrossRef111
Paul E. Sax, Caroline E. Sloan, Bruce R. Schackman, Philip M. Grant, Jian Rong, Andrew R. Zolopa, William Powderly, Elena Losina, Kenneth A. Freedberg. (2010) Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. HIV Clinical Trials 11:5, 248-259
CrossRef112
José A. Esté, Tomas Cihlar. (2010) Current status and challenges of antiretroviral research and therapy. Antiviral Research 85:1, 25-33
CrossRef113
Gerd Fätkenheuer, Christian Hoffmann, Jihad Slim, Régine Rouzier, Anther Keung, Jing Li, Michelle Treitel, Angela Sansone-Parsons, Claudia Kasserra, Edward OʼMara, Dirk Schürmann. (2010) Short-Term Administration of the CCR5 Antagonist Vicriviroc to Patients With HIV and HCV Coinfection Is Safe and Tolerable. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:1, 78-85
CrossRef114
Keith W Crawford, Chonghua Li, Anther Keung, Zhaohui Su, Michael D Hughes, Wayne Greaves, Daniel Kuritzkes, Roy Gulick, Charles Flexner. (2010) Pharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects (ACTG Protocol 5211). JAIDS Journal of Acquired Immune Deficiency Syndromes1
CrossRef115
Jennifer Jao, Christina M. Wyatt. (2010) Antiretroviral Medications: Adverse Effects on the Kidney. Advances in Chronic Kidney Disease 17:1, 72-82
CrossRef116
Felicitas C. Kühne, Jeremy Chancellor, Patrick Mollon, Daniela E. Myers, Michael Louie, William G. Powderly. (2010) A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals. HIV Clinical Trials 11:2, 80-99
CrossRef117
Laura Dickinson, Saye Khoo, David Back. (2010) Pharmacokinetics and drug–drug interactions of antiretrovirals: An update. Antiviral Research 85:1, 176-189
CrossRef118
Jocelyn S Downey, Nesrina Imami. (2010) T-cell dysfunction in HIV-1 infection: targeting the inhibitors. HIV Therapy 4:1, 83-99
CrossRef119
Masanori Hizue. (2010) Pharmacological profile and clinical findings of Maraviroc (Celsentri® Tablets). Folia Pharmacologica Japonica 136:6, 349-358
CrossRef120
Mark Nelson, Martin Fisher, Juan Gonzalez-Garcia, Jürgen K. Rockstroh, David Weinstein, Hernan Valdez, Howard Mayer, Elna van der Ryst, James M. Goodrich, Nathalie Dang. (2010) Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus Optimized Background Therapy in the MOTIVATE 1 and 2 Trials. HIV Clinical Trials 11:3, 145-155
CrossRef121
Rosa F Yeh, Rupali Jain, Hannah R Palmer. (2009) 49th ICAAC Annual Meeting: optimization of anti-infective use in the clinical setting. Expert Review of Anti-infective Therapy 7:10, 1167-1172
CrossRef122
Philip M. Grant, Sarah Palmer, Eran Bendavid, Annie Talbot, Debbie C. Slamowitz, Pat Cain, Stacy S. Kobayashi, Maya Balamane, Andrew R. Zolopa. (2009) Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. Journal of Clinical Virology 46:4, 305-308
CrossRef123
Sanjay Bhattacharya, Husam Osman. (2009) Novel targets for anti-retroviral therapy. Journal of Infection 59:6, 377-386
CrossRef124
Philip M Grant, Andrew R Zolopa. (2009) The use of resistance testing in the management of HIV-1-infected patients. Current Opinion in HIV and AIDS 4:6, 474-480
CrossRef125
Nina H Lin, Daniel R Kuritzkes. (2009) Tropism testing in the clinical management of HIV-1 infection. Current Opinion in HIV and AIDS 4:6, 481-487
CrossRef126
Jennifer R Tisoncik, Sarah E Belisle, Deborah L Diamond, Marcus J Korth, Michael G Katze. (2009) Is systems biology the key to preventing the next pandemic?. Future Virology 4:6, 553-561
CrossRef127
Yazdan Yazdanpanah. (2009) Multidrug resistance: a clinical approach. Current Opinion in HIV and AIDS 4:6, 499-506
CrossRef128
Jonathan B Angel, Wayne Greaves, Jianmin Long, Douglas Ward, Allan E Rodriguez, Daniele Scevola, Edwin DeJesus. (2009) Virologic and immunologic activity of PegIntron in HIV disease. AIDS 23:18, 2431-2438
CrossRef129
James A McKinnell, Michael S Saag. (2009) Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C–C motif) receptor 5 antagonists]. Current Opinion in HIV and AIDS 4:6, 513-517
CrossRef130
Mark W Hull, Viviane D Lima, Robert S Hogg, P Richard Harrigan, Julio SG Montaner. (2009) Epidemiology of treatment failure: a focus on recent trends. Current Opinion in HIV and AIDS 4:6, 467-473
CrossRef131
Vincent Soriano, Carlo-Federico Perno, Rolf Kaiser, Vincent Calvez, Jose M Gatell, Giovanni di Perri, Deenan Pillay, Juergen Rockstroh, Anna María Geretti. (2009) When and how to use maraviroc in HIV-infected patients. AIDS 23:18, 2377-2385
CrossRef132
Olena Stepanyuk, Tom S Chiang, Lisa L Dever, Sandra L Paez, Sharon M Smith, George Perez, Robert HK Eng. (2009) Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS 23:14, 1911-1913
CrossRef133
C William Wester, Hermann Bussmann, John Koethe, Claire Moffat, Sten Vermund, Max Essex, Richard G Marlink. (2009) Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Therapy 3:5, 501-526
CrossRef134
Pierre Corbeau, Jacques Reynes. (2009) CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS 23:15, 1931-1943
CrossRef135
Annette H Sohn, Jintanat Ananworanich. (2009) HAART for children with treatment failure. HIV Therapy 3:5, 485-499
CrossRef136
Barry Weatherley, Lynn McFadyen. (2009) Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. British Journal of Clinical Pharmacology 68:3, 355-369
CrossRef137
Wei Huang, Jonathan Toma, Eric Stawiski, Signe Fransen, Terri Wrin, Neil Parkin, Jeannette M. Whitcomb, Eoin Coakley, Frederick M. Hecht, Steven G. Deeks, Rajesh T. Gandhi, Susan H. Eshleman, Christos J. Petropoulos. (2009) Characterization of Human Immunodeficiency Virus Type 1 Populations Containing CXCR4-Using Variants from Recently Infected Individuals. AIDS Research and Human Retroviruses 25:8, 795-802
CrossRef138
Martin Stürmer, Hans Wilhelm Doerr, Lutz Gürtler. (2009) Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Medical Microbiology and Immunology 198:3, 147-155
CrossRef139
James A McKinnell, Hui-Yi Lin, Christa N Nevin, James H Willig, Graeme McFarland, Michael Genz, James L Raper, Lori L DeLaitsch, Joseph M Mrus, Winslow Klaskala, Michael J Mugavero, Michael S Saag. (2009) Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study. AIDS 23:12, 1539-1546
CrossRef140
Holly H. Kim, Eric S. Daar. (2009) Newer antiretroviral agents and how to use them. Current Infectious Disease Reports 11:4, 327-334
CrossRef141
Olga Latinovic, Alonso Heredia, Robert C. Gallo, Marv Reitz, Nhut Le, Robert R. Redfield. (2009) Rapamycin enhances aplaviroc anti-HIV activity: Implications for the clinical development of novel CCR5 antagonists. Antiviral Research 83:1, 86-89
CrossRef142
Elizabeth J Phillips, Simon A Mallal. (2009) Personalizing antiretroviral therapy: is it a reality?. Personalized Medicine 6:4, 393-408
CrossRef143
Graeme Moyle, Natasa Rajicic, James Goodrich, Howard Mayer, Hernan Valdez. (2009) Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials. AIDS 23:12, 1613
CrossRef144
John Archer, Michael S Braverman, Bruce E Taillon, Brian Desany, Ian James, P Richard Harrigan, Marilyn Lewis, David L Robertson. (2009) Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 23:10, 1209-1218
CrossRef145
L. Vandekerckhove, C. Verhofstede, D. Vogelaers. (2009) Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. Journal of Antimicrobial Chemotherapy 63:6, 1087-1096
CrossRef146
Mark A Boyd. (2009) Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS 4:3, 194-199
CrossRef147
Sarah L Pett. (2009) Immunotherapies in HIV-1 infection. Current Opinion in HIV and AIDS 4:3, 188-193
CrossRef148
Holly H. Kim, Eric S. Daar. (2009) Newer antiretroviral agents and how to use them. Current HIV/AIDS Reports 6:2, 55-62
CrossRef149
Panel de expertos de Gesida, Plan Nacional sobre el Sida. (2009) Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización febrero de 2009). Enfermedades Infecciosas y Microbiología Clínica 27:4, 222-235
CrossRef150
E. Poveda, E. Seclen, M. d. M. Gonzalez, F. Garcia, N. Chueca, A. Aguilera, J. J. Rodriguez, J. Gonzalez-Lahoz, V. Soriano. (2009) Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. Journal of Antimicrobial Chemotherapy 63:5, 1006-1010
CrossRef151
Daniel R Kuritzkes. (2009) HIV-1 entry inhibitors: an overview. Current Opinion in HIV and AIDS 4:2, 82-87
CrossRef152
Amalio Telenti. (2009) Safety concerns about CCR5 as an antiviral target. Current Opinion in HIV and AIDS 4:2, 131-135
CrossRef153
Alain Makinson, Jacques Reynes. (2009) The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Current Opinion in HIV and AIDS 4:2, 150-158
CrossRef154
José R. Santos, Josep M. Llibre, Elena Ferrer, Pere Domingo, Arkaitz Imaz, José Moltó, Raquel Martin-Iguacel, Carme Caum, Daniel Podzamczer, Bonaventura Clotet. (2009) Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression. HIV Clinical Trials 10:6, 432-438
CrossRef155
S. Moreno, B. Clotet, C. Sarría, E. Ortega, M. Leal, F. Rodriguez-Arrondo, R. Sánchez-de la Rosa, ALLEGRO Study Group. (2009) Prevalence of CCR5-tropic HIV-1 Among Treatment-Experienced Individuals in Spain. HIV Clinical Trials 10:6, 394-402
CrossRef156
Birgitt Dau, Mark Holodniy. (2009) Novel Targets for Antiretroviral Therapy. Drugs 69:1, 31-50
CrossRef157
Brian Conway. (2009) HAART in treatment-experienced patients in the 21st century: the audacity of hope. Future Virology 4:1, 39-41
CrossRef158
A. Heredia, O. Latinovic, R. C. Gallo, G. Melikyan, M. Reitz, N. Le, R. R. Redfield. (2008) Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proceedings of the National Academy of Sciences 105:51, 20476-20481
CrossRef159
Jacyntha A. Sterling. (2008) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 43:12, 1024-1030
CrossRef160
J.K. Rockstroh, J.C. Wasmuth. (2008) Rationaler Einsatz der modernen Substanzen bei HIV-Infektion. Der Internist 49:12, 1463-1470
CrossRef161
(2008) News in brief. Nature Medicine 14:11, 1140-1141
CrossRef162
Dolin, Raphael, . (2008) A New Class of Anti-HIV Therapy and New Challenges. New England Journal of Medicine 359:14, 1509-1511
Full Text163
Fätkenheuer, Gerd, Nelson, Mark, Lazzarin, Adriano, Konourina, Irina, Hoepelman, Andy I.M., Lampiris, Harry, Hirschel, Bernard, Tebas, Pablo, Raffi, François, Trottier, Benoit, Bellos, Nicholaos, Saag, Michael, Cooper, David A., Westby, Mike, Tawadrous, Margaret, Sullivan, John F., Ridgway, Caroline, Dunne, Michael W., Felstead, Steve, Mayer, Howard, van der Ryst, Elna, . (2008) Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. New England Journal of Medicine 359:14, 1442-1455
Full Text
